Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

PHASE4RecruitingINTERVENTIONAL

Enrollment

1,800

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

October 31, 2026

Conditions

Chikungunya Virus Infection

Interventions

BIOLOGICAL

IXCHIQ

Group of vaccinated arm will be with the IXCHIQ vaccine

Trial Locations (1)

RECRUITING

CHU La Réunion, Saint-Denis

All Listed Sponsors

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

collaborator

Région La Réunion

UNKNOWN

collaborator

ARS La Réunion

UNKNOWN

collaborator

Direction Générale de l'offre de Soins (DGOS)

UNKNOWN

lead

Centre Hospitalier Universitaire de la Réunion

OTHER